The Medical Advisor

Fenbendazole and ivermectin, both antiparasitic drugs, have shown promising potential in cancer treatment. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin , on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Table of Contents Introduction What is Ivermectin What is Fenbendazole Chemical Structure and Mechanism of Action Comparing the Spectrum of ‍Activity The Role of Ivermectin in Cancer Symptoms The Role of Fenbendazole in Cancer Symptoms Safety ⁣Profile and Side Effects: Assessing Risks and Tolerability Should You Use Ivermectin or Fenbendazole for Cancer? Ivermectin and Fenbendazole for Cancer Route of Administration and Dosage Forms Ivermectin dosage for Cancer Fenbendazole dosage for Cancer Cost-Effectiveness and Availability: Evaluating Economi...

Introduction Cancer care has become increasingly sophisticated at the molecular level. Genomic sequencing, targeted therapies, and immuno-oncology have transformed how tumors are classified and treated. Yet despite these advances, long-term outcomes for many cancers remain stubbornly limited . One reason is structural rather than technological. Modern cancer care is fragmented. Oncology focuses on tumor-directed interventions, while primary care manages metabolic health, cardiovascular risk, inflammation, and aging. These domains rarely intersect in a coordinated way. From a systems perspective, this separation makes little biological sense. Coupling oncology with primary care is emerging as a critical — and largely missing — strategy for durable cancer control. Cancer Is Not an Isolated Tumor Problem Cancer does not develop or progress in isolation. It arises within a host environment shaped by metabolism, immune function, inflammation, hormonal signaling, and mitochondrial health. M...

Modern medicine is not fragmented — it’s incomplete . The separation between prevention, chronic disease, cancer treatment, and AI is largely historical, not biological. At the level where disease actually emerges — metabolism, inflammation, immunity, and network failure — these domains converge. OneDayMD is built around that convergence. 1. Disease Is a Systems Failure, Not a Single Defect Most chronic diseases — cancer, diabetes, cardiovascular disease, neuro-degeneration — arise from interacting biological systems , not isolated mutations. Common upstream drivers include: Insulin resistance and metabolic dysfunction Chronic inflammation Immune dysregulation Mitochondrial stress Hormonal and nutrient signaling imbalance These processes: Develop years before diagnosis Cut across organ systems Are modifiable long before disease becomes irreversible. A systems problem requires systems-level tools . Related:  Systems-Level Cancer Control: Why Cancer Treatment Must Go Beyond Targeted...

Abstract Cancer remains a leading cause of global mortality, increasingly recognized as a metabolic disorder characterized by dysregulated energy pathways such as aerobic glycolysis (Warburg effect) and dependency on fermentable substrates like glucose and glutamine. Traditional therapies, while effective, often exacerbate mitochondrial dysfunction and foster resistance. This review synthesizes recent evidence on metabolic interventions and repurposed drugs targeting cancer stem cells (CSCs), restoring oxidative phosphorylation (OxPhos), and modulating the tumor microenvironment (TME). Drawing from over 1,000 peer-reviewed studies, including meta-analyses, randomized controlled trials (RCTs), case series, and preclinical data, we prioritize human evidence to outline core principles, a curated top 10 interventions ranked by CSC targeting, metabolic disruption, clinical efficacy, and safety, integrated protocols, and future directions. Emphasis is placed o...